ReviewPharmaceutics2025
Small-Molecule Probes: Recent Progress in the Rapid Detection of Carbapenemase-Producing Bacteria.
Review in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Novel Insights into Carbapenem Resistance: Mechanisms, Diagnostics, and Future Directions.Antibiotics (Basel, Switzerland) · 2026Review
- The oral cavity as a reservoir for resistance- and hypervirulence-associated genes ofFrontiers in microbiology · 2026Article
- Revisiting the Metallo-International journal of microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
As the last resort and one of the most crucial antibiotics for multidrug-resistant bacteria, carbapenem is considered the best hope for treating bacterial infections. However, the prompt emergence of carbapenemase-producing bacteria (CPB) poses a striking global health threat. Thus, accurate and rapid methods for the detection of carbapenemase are being requested to guide precise diagnosis, appropriate treatment strategies, and antibiotic stewardship. Although genotypic, phenotypic, and biochemical methods are currently used in clinical practice for CPB detection, they each have their problems that cannot commendably meet the need. In recent years, small-molecule probes have made significant progress and breakthroughs in the rapid detection and subtyping of CPB, providing insights and innovative solutions for the ultra-sensitive detection of CPB. In this minireview, some of the advances, namely, chromogenic probes and methods, fluorogenic probes, dual fluorogenic-chromogenic probes, a chemiluminescent probe, and a novel label-free intracellular calorimetric approach, are summarized, appreciated, and discussed. These methods offer high sensitivity, specificity, and accuracy in a short period in clinical settings without the utilization of sophisticated equipment or professional personnel. We hope that this minireview can provide a reference for the development of rapid detection of CPB and eventually contribute to antibiotic resistance management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.